Boston Scientific Loses Share To J&J; Rebate Program Could Buoy Sales

Boston Scientific's share of the U.S. drug-eluting stent market fell four percentage points to 55% during the third quarter as the firm failed to stop Johnson & Johnson/Cordis from stealing market share